Legis Daily

To provide for the mandatory recall of drugs regulated by the Food and Drug Administration.

USA115th CongressHR-1108| House 
| Updated: 2/17/2017
Rosa L. DeLauro

Rosa L. DeLauro

Democratic Representative

Connecticut

Cosponsors (4)
James R. Langevin (Democratic)Jamie Raskin (Democratic)Louise McIntosh Slaughter (Democratic)Lloyd Doggett (Democratic)

Commerce, Manufacturing, and Trade Subcommittee, Energy and Commerce Committee

  • Introduced
  • In Committee
  • On Floor
  • Passed Chamber
  • Enacted
Recall Unsafe Drugs Act of 2017 This bill amends the Federal Food, Drug, and Cosmetic Act (FFDCA) to require producers of medications to notify the Food and Drug Administration (FDA) of the identity and location of a medication if the producer has reason to believe: (1) that the medication is adulterated or misbranded; and (2) there is a reasonable probability that the use or consumption of, or exposure to, the medication will cause a threat of serious adverse health consequences or death to humans or animals. The FDA may: (1) request that the distributor of a medication that is in violation of the FFDCA voluntarily recall the medication; (2) require the distributor of a medication that may cause serious adverse health consequences to immediately cease distribution of the medication; (3) recall a medication for which distribution has been ceased after giving the distributor an opportunity for an informal hearing; and (4) immediately recall a medication that presents an imminent threat of serious adverse health consequences. Distributors may appeal these FDA orders. In the case of a recall, the FDA must notify consumers and state and local health officials to whom the medication was, or may have been, distributed. Medication distributors must have a recall plan in effect.
View Full Text

Suggested Questions

Get AI-generated questions to help you understand this bill better

Timeline
Feb 16, 2017
Introduced in House
Feb 16, 2017
Referred to the House Committee on Energy and Commerce.
Feb 17, 2017
Referred to the Subcommittee on Digital Commerce and Consumer Protection.
  • February 16, 2017
    Introduced in House


  • February 16, 2017
    Referred to the House Committee on Energy and Commerce.


  • February 17, 2017
    Referred to the Subcommittee on Digital Commerce and Consumer Protection.

Health

Administrative remediesConsumer affairsDepartment of Health and Human ServicesDrug safety, medical device, and laboratory regulationGovernment information and archives

To provide for the mandatory recall of drugs regulated by the Food and Drug Administration.

USA115th CongressHR-1108| House 
| Updated: 2/17/2017
Recall Unsafe Drugs Act of 2017 This bill amends the Federal Food, Drug, and Cosmetic Act (FFDCA) to require producers of medications to notify the Food and Drug Administration (FDA) of the identity and location of a medication if the producer has reason to believe: (1) that the medication is adulterated or misbranded; and (2) there is a reasonable probability that the use or consumption of, or exposure to, the medication will cause a threat of serious adverse health consequences or death to humans or animals. The FDA may: (1) request that the distributor of a medication that is in violation of the FFDCA voluntarily recall the medication; (2) require the distributor of a medication that may cause serious adverse health consequences to immediately cease distribution of the medication; (3) recall a medication for which distribution has been ceased after giving the distributor an opportunity for an informal hearing; and (4) immediately recall a medication that presents an imminent threat of serious adverse health consequences. Distributors may appeal these FDA orders. In the case of a recall, the FDA must notify consumers and state and local health officials to whom the medication was, or may have been, distributed. Medication distributors must have a recall plan in effect.
View Full Text

Suggested Questions

Get AI-generated questions to help you understand this bill better

Timeline
Feb 16, 2017
Introduced in House
Feb 16, 2017
Referred to the House Committee on Energy and Commerce.
Feb 17, 2017
Referred to the Subcommittee on Digital Commerce and Consumer Protection.
  • February 16, 2017
    Introduced in House


  • February 16, 2017
    Referred to the House Committee on Energy and Commerce.


  • February 17, 2017
    Referred to the Subcommittee on Digital Commerce and Consumer Protection.
Rosa L. DeLauro

Rosa L. DeLauro

Democratic Representative

Connecticut

Cosponsors (4)
James R. Langevin (Democratic)Jamie Raskin (Democratic)Louise McIntosh Slaughter (Democratic)Lloyd Doggett (Democratic)

Commerce, Manufacturing, and Trade Subcommittee, Energy and Commerce Committee

Health

  • Introduced
  • In Committee
  • On Floor
  • Passed Chamber
  • Enacted
Administrative remediesConsumer affairsDepartment of Health and Human ServicesDrug safety, medical device, and laboratory regulationGovernment information and archives